Detection and quantitation of HBV DNA in miniaturized samples: Multi centre study to evaluate the performance of the COBAS® AmpliPrep/COBAS® TaqMan® hepatitis B virus (HBV) test v2.0 by the use of plasma or serum specimens

Laboratory analysis of blood specimens is an increasingly important tool for rapid diagnosis and control of therapy. So, miniaturization of test systems is needed, but reduced specimens might impair test quality. For rapid detection and quantitation of HBV DNA, the COBAS® AmpliPrep/COBAS® TaqMan® HBV test has proved a robust instrument in routine diagnostic services. The test system has been modified recently for application of reduced samples of blood plasma and for blood serum, too.The performance of this modified COBAS® AmpliPrep/COBAS® TaqMan® HBV v2.0 (HBV v2.0 (this test is currently not available in the USA)) test was evaluated by comparison with the former COBAS® AmpliPrep/COBAS® TaqMan® HBV v1.0 (HBV v1.0) test. In this study a platform correlation of both assay versions was done including 275 HBV DNA positive EDTA plasma samples. Comparable results were obtained (R2 = 0.97, mean difference −0.03 log10 IU/ml). The verification of equivalency of the sample matrix (plasma vs. serum samples tested in HBV v2.0 in the same run) showed comparable results for all 278 samples with a R2 = 0.99 and a mean difference of 0.06 log10 IU/ml.In conclusion, the new test version HBV v2.0 is highly specific and reproducible and quantifies accurately HBV DNA in EDTA plasma and serum samples from patients with chronic HBV infection.